Back to top
more

Royalty Pharma (RPRX)

(Real Time Quote from BATS)

$26.69 USD

26.69
42,050

+0.25 (0.95%)

Updated Aug 13, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Financial - Miscellaneous Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.

Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.05% and 1.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

MVB Financial (MVBF) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

MVB Financial (MVBF) delivered earnings and revenue surprises of -22.50% and 9.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

How to Find Strong Finance Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday

by Zacks Equity Research

Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.

Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.08% and 6.79%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 6.78% and 4.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Royalty Pharma (RPRX)

by Zacks Equity Research

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Here's What to Expect From Assurant's (AIZ) Q1 Earnings

by Zacks Equity Research

Assurant's (AIZ) first-quarter performance is likely to have benefited from higher yields in fixed maturity securities, lender-placed average insured values and organic growth across all products.

Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

RPRX or BX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RPRX vs. BX: Which Stock Is the Better Value Option?